wallstreet:online
40,20EUR | +0,05 EUR | +0,12 %
DAX+1,31 % EUR/USD-0,02 % Gold-0,59 % Öl (Brent)0,00 %

CYGNUS!!!Geht da was...Übernahme durch Animas,10 Mill.$$$ - 500 Beiträge pro Seite



Beitrag schreiben

Begriffe und/oder Benutzer

 

für 10 Millionen Dollar,Cygnus hat eine Marktkap. von 3,12 Mill.-heisst das,der Kurs verdoppelt sich heute...und noch mehr????


folgende meldung auf CBS:

Animas to Acquire Key Cygnus Technology
Thursday December 16, 8:06 pm ET
Acquisition to Help Animas Develop and Broaden Its Next-Generation Glucose Monitoring Product Portfolio


WEST CHESTER, Pa.--(BUSINESS WIRE)--Dec. 16, 2004--Animas Corporation (NASDAQ NM:PUMP - News) today announced that it has entered into a definitive agreement with Cygnus, Inc. (OTC BB:CYGN - News) pursuant to which Animas will acquire substantially all of Cygnus` intellectual property rights, fixed assets, supplier, manufacturing and license agreements, inventory and tangible personal property, for $10 million in cash. Under the terms of the agreement, Animas will take ownership of over 237 U.S. and foreign patents in the fields of continuous glucose sensing, extraction of interstitial fluid by reverse electro-iontophoresis and electrochemical sensors. Animas will not assume any of Cygnus`s liabilities in this transaction other than customary obligations under assumed contracts.
ADVERTISEMENT


"Cygnus has a uniquely strong patent portfolio in the field of glucose sensing," says Dr. Kathy Crothall, President and CEO of Animas. "Cygnus electrochemical sensor technology is quite mature, with Cygnus having produced over ten million electrochemical sensors. The marriage of the micro-needle technology recently licensed from Debiotech to the Cygnus electrochemical sensor technology offers the possibility of a future generation sensor with improved accuracy and less skin irritation than Cygnus` present technology. With this transaction, Animas will add a compelling, minimally-invasive technology to its continuous glucose sensing portfolio. These new technologies nicely complement Animas` long-term implantable sensor development, and when coupled with our superior insulin pump technology, substantially strengthen Animas` position in this important area."

The consummation of the transaction is subject to the approval of Cygnus`s stockholders and other customary conditions. Upon consummation of the transaction, Cygnus will cease operations and, at a time to be determined in the future, dissolve under applicable law.

About Animas

Animas, a leading maker of insulin infusion pumps and related products, is dedicated to improving diabetes management and making insulin pump therapy easier for patients with insulin requiring diabetes and healthcare professionals through product innovation, exemplary customer support and superior customer education. For more information on Animas, visit http://www.animascorp.com or call Animas Corporation at 877-937-7867.

Statements in this press release or made by management from time to time regarding Animas Corporation, or the transaction with Cygnus and its anticipated benefits, that are not historical facts are forward-looking statements and are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. Any such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The following factors, among others, could cause Animas` actual results to differ materially from those described in a forward-looking statement: the technical issues or the failure of the IR1200 to gain significant market acceptance; failure to capture recurring purchases of ancillary supplies by patients using Animas` pumps; any significant disruption with vendors; any failure to achieve and then maintain profitability; failure to commercialize the Debiotech technology and realize its anticipated benefits; the failure of Animas` ezSet Infusion Set to be fully-developed or commercially accepted; technological breakthroughs in diabetes monitoring, treatment, or prevention that could render Animas` products obsolete; failure to comply with any FDA or foreign regulations; an inability to attract and retain personnel; competition; an inability to adequately protect Animas` intellectual property; product liability lawsuits; failure to secure or retain third party insurance coverage or reduced reimbursement for Animas` products by third party payors; and our ability to complete the transaction with Cygnus and realize its anticipated benefits. This list is intended to identify only certain of the principal factors that could cause actual results to differ. Readers are referred to the reports and documents filed from time to time by Animas Corporation with the Securities and Exchange Commission for a discussion of these and other important risk factors. Readers are cautioned not to place undue reliance on forward-looking statements, which are made as of the date of this press release. Animas Corporation undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or for any other reason.

--------------------------------------------------------------------------------
Contact:
Animas Corporation
Investor and Media Contact:
Rick Baron, 610-644-8990, ext. 1168
richard.baron@animascorp.com
8:19pm 12/16/04
Animas to buy Cygnus for $10 million cash (PUMP, CYGN) By Chelsea Bellows
SAN FRANCISCO (CBS.MW) -- Animas Corp. (PUMP) , which makes insulin infusion pumps, said late Thursday that it plans to purchase "substantially all" of Cygnus Inc. (CYGN) for about $10 million in cash. Under the terms of the agreement, Animas will take ownership of over 237 of Cygnus` U.S. and foreign patents.


Cygnus hatte laut Yahoo gestern eine Marktk. von ca. $3,5 Mio., animas zahlt $10 Mio in Cash, also knapp 3mal soviel.
Der Kurs hier ist viel zu niedrig.
Die Market Maker in Amerika müssen heute auch ihre Short-Positionen decken, das könnte einen fetten Spike geben heute, men KZ liegt bei 0,2 Euro!!!

Gruß
ITG
Danke für den Hinweis :)

Kurs sollte auf mind. 24 $-Cent laufen - was in etwa 0,18€ wären.
Nun die Meldung dazu von Cygnus:

Cygnus and Animas Corporation Enter Into $10 Million Asset Purchase Agreement



REDWOOD CITY, Calif., Dec. 17 /PRNewswire-FirstCall/ -- Cygnus, Inc. (OTC Bulletin Board: CYGN) announced today that it had entered into an Asset Purchase Agreement with Animas Corporation (Nasdaq: PUMP) pursuant to which Animas will acquire certain assets of Cygnus (the "Acquisition") for a purchase price of $10 million in cash. The assets to be sold by Cygnus to Animas include substantially all of Cygnus` intellectual property rights, fixed assets, supplier, manufacturing and license agreements, inventory and tangible personal property.

Assets excluded from the Acquisition include Cygnus` cash and cash equivalents, accounts receivable and its arbitration claim against Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company.

The Asset Purchase Agreement was unanimously approved by the Cygnus Board of Directors. Cygnus currently expects the Acquisition to close in the first quarter of 2005, subject to certain conditions. First Albany Capital Inc. served as the Company`s exclusive financial advisor for this transaction.

Cygnus will submit for a stockholder vote two proposals: to approve the Acquisition and to approve a plan of dissolution. Cygnus will be filing a proxy statement and other relevant documents concerning the transaction with the Securities and Exchange Commission (SEC). The Acquisition and the liquidation proposals are not conditioned upon one another.

If the Acquisition and plan of dissolution are approved by stockholders and the Acquisition closes, Cygnus will complete the liquidation of its remaining assets and satisfy its remaining obligations. Upon the closing of the Acquisition, Cygnus would settle its obligations with Sanofi Aventis and the lien on Cygnus` assets would be released. Cygnus would use its remaining cash to fund its further scaled-back operating expenses and the expenses of prosecuting the arbitration claim against Ortho-McNeil Pharmaceutical, Inc. As previously disclosed, Cygnus is seeking $34.6 million in damages in this arbitration. The outcome of the arbitration matter is inherently uncertain. There is risk inherent in all litigation. Accordingly, it is impossible to predict whether Cygnus will prevail in the arbitration matter, or to determine the amount of money, if any, Cygnus will recover. Upon the resolution of the arbitration, Cygnus would make a distribution to stockholders of any remaining liquidation proceeds.

If the Acquisition is not completed, whether due to the failure of stockholders to approve the transaction or any other reason, Cygnus would likely file for, or be forced to resort to, bankruptcy protection and it is unlikely that there would be funds available for a distribution to stockholders.

In a separate transaction, Cygnus signed a lease termination agreement with its Redwood City facility landlord whereby Cygnus paid a termination fee of $500,000, forfeited its security deposit of approximately $77,600 and will leave certain trade fixtures and personal property in the facility when the Company vacates on or before March 31, 2005. The early termination relieves the Company of its contractual obligations of approximately $3.7 million for the remaining lease term through April 30, 2009.

Stockholders of Cygnus are urged to read the proxy statement and any other relevant documents filed with the SEC when they become available because they will contain important information. Investors and security holders can obtain free copies of the proxy statement and other relevant documents when they become available by contacting Cygnus, Inc., 400 Penobscot Drive, Redwood City, CA 94063-4719. In addition, documents filed with the SEC by Cygnus will be available free of charge at the SEC`s web site at www.sec.gov.

Information regarding the identity of the persons who may, under SEC rules, be deemed to be participants in the solicitation of stockholders of Cygnus in connection with the transaction, and their direct and indirect interest, by security holding or otherwise, in the solicitation, will be set forth in a proxy statement that will be filed by Cygnus with the SEC.

The GlucoWatch G2(R) Biographer and AutoSensors will remain available for purchase until the completion of the Acquisition. To purchase these products, call 1-866-GLWATCH (1-866-459-2824). After completion of the Acquisition, then future availability of GlucoWatch G2(R) Biographer products will be determined by Animas.

ABOUT CYGNUS

Cygnus (www.cygn.com and www.glucowatch.com) has developed, manufactured and commercialized new and improved glucose-monitoring devices. Cygnus` products are designed to provide more data to individuals and their physicians and enable them to make better-informed decisions on how to manage diabetes. The three generations of Cygnus` GlucoWatch Biographers are the only products approved by the FDA that provide frequent, automatic and non-invasive measurement of glucose levels. Cygnus believes its products represent the most significant commercialized technological advancement in self-monitoring of glucose levels since the advent of "finger-stick" blood glucose measurement approximately 20 years ago. The Biographer is not intended to replace the common "finger-stick" or alternative site testing methods, but is indicated as an adjunctive device to supplement blood glucose testing to provide more complete, ongoing information about glucose levels.

Some of the statements in this news release are forward-looking statements that involve risks and uncertainties. These forward-looking statements include statements about Cygnus` plans, objectives, expectations, intentions and assumptions and other statements contained in this news release that are not statements of historical fact. Forward-looking statements include, but are not limited to statements about the consummation of the Acquisition including obtaining stockholder approval, the outcome of the Ortho-McNeil Pharmaceutical arbitration, the ability to satisfy Cygnus` obligations without resorting to protection under bankruptcy laws, the timing and amounts of distribution of liquidation proceeds to stockholders, the capabilities and potential of the GlucoWatch G2 Biographer business, Cygnus` ability to achieve market acceptance of the GlucoWatch G2 Biographer, Cygnus` ability to manufacture the GlucoWatch G2 Biographer, and Cygnus` plans for other commercialization alliances. In some cases, you can identify these statements by words such as "may," "will," "should," "estimates," "predicts," "potential," "continues," "strategy," "believes," "anticipates," "plans," "expects," "intends" and similar expressions. Cygnus cannot guarantee future results, levels of activity, performance or achievements. Cygnus` actual results and the timing of certain events may differ significantly from the results and timing discussed in this news release. With respect to the sale of assets and liquidation, many of the risks and uncertainties involved are beyond Cygnus` control. These risks and uncertainties include, but are not limited to, the ability to obtain stockholder approval of the transactions and to satisfy the other closing conditions to the Acquisition, the risk that Cygnus incurs additional liabilities that Cygnus does not now anticipate, that Cygnus` expenses, including the expenses in prosecuting the arbitration matter, may be higher than expected whether due to length of time involved or otherwise, that the settlement of Cygnus` liabilities could be higher than expected, and, since litigation is inherently uncertain, the possibility that Cygnus receives no recovery at all in the arbitration matter. All forward-looking statements included in this news release are based on information available to Cygnus on the date hereof, and Cygnus assumes no obligation to update any such forward-looking statements.

NOTE: "GlucoWatch" and "G2" are registered trademarks of Cygnus, Inc.
SOURCE Cygnus, Inc.
-0- 12/17/2004
/CONTACT: Cygnus Corporate Communications, +1-650-369-4300 (option 2)/
/Web site: http://www.cygn.com /
(CYGN PUMP)

CO: Cygnus, Inc.; Animas Corporation
ST: California
IN: MTC CPR HEA OTC
SU: TNM

MP-MW
-- SFF009 --
0036 12/17/200406:00 ESThttp://www.prnewswire.com
Und das Filing gleich dazu:

Form 8-K for CYGNUS INC /DE/


--------------------------------------------------------------------------------

17-Dec-2004

Entry Material Agreement, Financial Statements and Exhibits



Item 1.01. Entry into a Material Definitive Agreement.
On December 17, 2004, Cygnus, Inc. issued a press release announcing that it had entered into an Asset Purchase Agreement for the sale of substantially all of Cygnus` intellectual property rights, fixed assets, supplier, manufacturing and license agreements, inventory and tangible personal property, to Animas Corporation for $10.0 million in cash. Assets excluded from the sale include Cygnus` cash and cash equivalents, accounts receivable and its arbitration claim against Ortho-McNeil Pharmaceutical, Inc., a Johnson & Johnson company.

The Asset Purchase Agreement was unanimously approved by the Cygnus Board of Directors. Subject to the approval of its stockholders, Cygnus intends to wind up its business in accordance with applicable law following the closing of the asset sale, and at an appropriate time thereafter effect a complete liquidation and dissolution. The asset sale and the liquidation proposals are not conditioned upon one another.

Cygnus currently expects the asset sale to close in the first quarter of 2005, subject to certain conditions, including the approval of the stockholders of Cygnus.

In a separate transaction, Cygnus signed a lease termination agreement with its Redwood City facility whereby Cygnus paid a termination fee of $500,000, forfeited its security deposit of approximately $77,600 and will leave certain trade fixtures and personal property in the facility when the Company vacates on or before March 31, 2005. The early termination relieves the Company of its contractual obligations of approximately $3.7 million for the remaining lease term through April 30, 2009.

A copy of the press release and Asset Purchase Agreement are attached hereto as Exhibits 99.1, 99.2 and 99.3, and are incorporated herein by reference.





Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.


Exhibit Number Description
-------------- ---------------------------------------------------------------------
99.1 Press Release by Cygnus, Inc. dated December 16, 2004 referred to in
Item 1.01 above.

99.2 Asset Purchase Agreement between Cygnus, Inc., Animas Corporation and
Animas Technologies LLC, dated December 16, 2004.

99.3 Lease Termination Agreement between Cygnus, Inc. and Metropolitan
Life Insurance Company, dated December 16, 2004.
na, da ist der MM am XTR wohl am spielen:

Xetra CG7 EUR 0,050 0,110 + 0,060 + 120,00 % 1 12

(12 stück - das werden aber hohe gebühren/stück)
guck dir mal was ich im anderen thread geschrieben habe. natürlich gibt es 10 mio, aber die gehen eben nicht zwangsläufig an die aktionäre, denn das unternehmen wird nicht verkauft sondern nur der kern.
Soweit ich das aus dem englischen übersetzen konnte
hat die Firma noch etwa 12 Mio Verbindlichkeiten und
etwa 12 Mio an Cash und Anlagevermögen.
Animas kauft alle Patente und Lizenzen nicht jedoch
Cash und Anlagevermögen!!
Was mich jedoch zu Spekulationen animiert ist der
Rechtsstreit gegen Ortho-McNeil Pharmaceutical wo
eine Summe in Höhe von etwa 34 Mio Dollar erwartet wird!
Sollte der Rechtsstreit positiv ausfallen würde sich die
Aktie vervielfachen !!!:):):)

Da mein Wirtschaftsenglisch leider nicht so gut ist
hoffe ich alles richtig verstanden zu haben !
Würde mich freuen auch noch was von anderen darüber zu lesen!
Informationsquellen: www.finanznachrichten.de
www.nasdaq.com
CYGNUS wird steigen !! :) :)
Ich habe den Verdacht da kauft einer gezielt
Aktien auf !!
Wäre nicht auszuschließen wenn sich plötzlich
jemand anderes außer Animas dafür interessieren
würde !
Diese GlucoWatch funktioniert ja schließlich.
Man muß nur mal die Entwicklungskosten rechnen !!!
Der Käufer würde zur Zeit sehr günstig
an alle Patente und Lizenzen rankommen.
Im Moment steigen die Umsätze in den USA auch wieder
stark an !!! ( teilweise 100000 Stück )
Vielleicht haben wir ja noch unser nachträgliches
Weihnachtsgeschenk !!!:) :) :) :)
Ich denke das Ortho McNeil CYGNUS aufkaufen wird !!:):)
Sie würden nur davon profitieren !!
Der Rechtsstreit wäre beendet und Ortho würde sehr
günstig an Patente und Lizenzen kommen !
Dieses Wissen könnten sie gut für ihr eigen entwickeltes Gerät verwenden !
Ortho McNeil muß sich nur beeilen sonst geht das ganze
an Animas !!!:):)


Beitrag zu dieser Diskussion schreiben


Es handelt sich hier um einen ältere Diskussionen, daher ist das Schreiben in dieser Diskussion nicht mehr möglich. Bitte eröffnen Sie hier ein neue Diskussion.